The goal of this clinical trial is to evaluate the effectiveness of ketogenic diet in patients with MELAS syndrome. The main questions it aims to answer are: Clarify the curative effects of ketogenic diet in the treatment of MELAS disease. Prevent the aggravation of MELAS disease, and improve the quality of life of patients. Provide reliable evidence-based medical basis for the clinical application of ketogenic diet in the treatment of MELAS syndrome patients. The clinical data of the participants treated with ketogenic diet will be collected, including the completion of ketogenic diet and clinical data at the start of treatment and after 1 month, 3 months, 6 months and 12 months
Ketogenic diet initiation and follow-up: 1. Before starting ketogenic diet treatment, patients with abnormal indexes such as liver, kidney, lipid, humoral immunity, hematuria, routine biochemical, electrolyte, trace elements and bone metabolism should be excluded, energy and nutrients should be calculated according to their height and weight, and patients will be taught with ketogenic diet treatment education 2. Patients were initiated ketogenic diet after a short period of fasting (fasting no more than 48 hours). After treatment was initiated, 13 of the calculated target energy was given on the first day, 23 of the target energy was given on the second day, and the target amount was reached on the third day. Nutritionists made appropriate adjustments to the target energy according to the level of blood keto measured by patients 3. Weekly follow-up via telemedicine system or social media, outpatient follow-up at the initiation of ketogenic therapy and at 1 month, 3 months, 6 months, and 12 months respectively. Outpatient follow-up was done in a joint clinic with a dietitian and a neurologist to evaluate the effects and side effects of ketogenic therapy on a compliant diet and related clinical examinations Clinical data collection: 1. Demographic information and Medical history collection Gender, age, education level age of onset, genetic test, drug use, past history, personal history, family history 2. Clinical symptom collection According to the Newcastle Mitochondrial Disease Adult Scale(NMDAS), including migraine headaches, seizures, stroke-like episodes and etc. 3. Biochemical indicators Blood glucose, keto, lactate and pyruvate monitoring, dietary status, dietary ratio changes, energy changes, weight changes 4. Cognitive function assessment Cognitive function was assessed using Fepsy software 5. Diagnostic Examination Cranial MRI, scalp EEG
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Ketogenic diet (KD) is a high-fat, low-carbohydrate and moderate protein diet pattern, suitable for refractory epilepsy, glucose carrier protein 1 deficiency, pyruvate dehydrogenase deficiency, tumors and some genetic metabolic diseases. The ketogenic diet has been used to treat epilepsy for nearly 100 years, and its safety has been recognized by the medical community. In 2015, the ketogenic diet was included in the "Clinical Diagnosis and Treatment Guidelines - Epilepsy Volume" and became a commonly used treatment for refractory epilepsy.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Change from Baseline Clinical Symptom Score in 1 Year
According to the newcastle mitochondrial disease adult scale(NMDAS), including migraine headaches, seizures, stroke-like episodes and etc.
Time frame: Baseline, 1 month, 3 months, 6 months and 12 months
Change from Baseline Biochemical indicators in 1 Year
Blood glucose
Time frame: Baseline, 1 month, 3 months, 6 months and 12 months
Change from Baseline Biochemical indicators in 1 Year
keto, lactate and pyruvate monitoring
Time frame: Baseline, 1 month, 3 months, 6 months and 12 months
Hamilton Anxiety Scale (HAMA)
Change from Baseline Cognitive Function in 1 Year. Cognitive function was assessed using "Fepsy" software
Time frame: Baseline, 1 month, 3 months, 6 months and 12 months
Hamilton Depression Scale(HAMD
Change from Baseline Cognitive Function in 1 Year . Cognitive function was assessed using "Fepsy" software
Time frame: Baseline, 1 month, 3 months, 6 months and 12 months
Wechsler Intelligence Scale(WISC)
Change from Baseline Cognitive Function in 1 Year . Cognitive function was assessed using "Fepsy" software
Time frame: Baseline, 1 month, 3 months, 6 months and 12 months
Mini-mental State Examination(MMSE)
Change from Baseline Cognitive Function in 1 Year . Cognitive function was assessed using "Fepsy" software
Time frame: Baseline, 1 month, 3 months, 6 months and 12 months
Change from Baseline Diagnostic Examination in 1 Year
Cranial MRI(multimodal) Scalp EEG to evaluate posterior head α rhythm, discharge index, interictal epileptic discharges
Time frame: Baseline, 1 month, 3 months, 6 months and 12 months
Demographic Information and Medical History Collection
Gender, age, education level age of onset, genetic test, drug use, past history, personal history, family history
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.